Move to topTop
January 19, 2012

Terumo Corporation announced today that it will establish a new production factory in Yamaguchi Prefecture, Japan. The objectives for newly establishing the factory are to increase the production of interventional systems products to meet growing global demands, to ensure its production capability for Drug and Device products* including ones for pain management, for which demand will grow in the future, and to further decentralize its production base for business continuity planning (BCP) perspective.

Terumo Corporation is to sign an agreement to build the facility with Yamaguchi City on January 23, 2012. The Company will invest a total of approximately 30 billion yen in the factory, which is scheduled to commence operations around the first quarter of FY2015.

  • * Drug and device products include syringes and infusion containers that have been pre-filled with therapeutic agents and other drugs. Through the combination of such drugs and medical devices, these products increase added value.

About Terumo Corporation's global production system

Terumo Corporation is accelerating its growth globally, and plans to expand its outside of Japan production ratio in line with its ratio of outside of Japan net sales, which account for over half of its total. However, certain highly advanced and precise production technologies are difficult to transfer outside of Japan. Accordingly, Terumo Corporation has designated production factories in Japan as mother production factories that develop core technologies for advanced manufacturing and refine production technologies that underpin the amelioration of products.

Background for newly establishing the Yamaguchi Factory

The sales for interventional systems products is continuing on a path of double-digit growth worldwide, and drug and device products are expected to grow in sales in the future. Accordingly, Terumo Corporation decided to establish this production factory in Japan as these products require highly advanced production technologies which are difficult to transfer outside. With the establishment of the Yamaguchi factory, Terumo Corporation will also further decentralize its production bases in Japan, which are currently located closely together in Shizuoka and Yamanashi prefectures, to ensure the company's responsibility to continue the stable supply of products even in the event of a disaster or other incident to put BCP in effect.

Terumo Corporation will globally expand its production system while meeting growing demands for medical treatment around the world with its corporate mission of "Contributing to Society through Healthcare."

Yamaguchi Factory Overview

Company Name: Terumo Yamaguchi Corporation

Location: Yamaguchi Techno Park, Yamaguchi city, Yamaguchi, Japan

Site Area: about 96,000m2 (land area); about 50,000m2 (total floor space)

Establishment Date: December, 2011

Projected Operation Commencement: the first quarter of FY2015

Production Items: Interventional systems products, Drug and Device products

including the ones for pain management

Number of Associates: about 130 persons (at the time of production start)

Target Markets: Japan and Other area

Target Sales: 30 billion yen (FY 2020)

Reference: Principal Production Factories of Terumo Corporation

Japan:

Fujinomiya Factory, Ashitaka Factory (Shizuoka Prefecture)

Kofu Factory (Yamanashi Prefecture)

Outside Japan:

Terumo Medical Corp. (USA)

Terumo Europe N.V. (Belgium)

Terumo Penpol Ltd. (India)

Terumo Medical Products (Hangzhou) Co., Ltd.

Terumo (Philippines) Corporation

Terumo Vietnam Co., Ltd. etc.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.